论文部分内容阅读
目的:通过研究SMARCB1在肝细胞癌(hepatocellular carcinoma,HCC)组织的表达,阐明其对HCC的早期诊断及预后的作用。方法:在癌症基因组图集(The Cancer Genome Atlas,TCGA)数据库中筛选出SMARCB1基因,运用免疫组织化学(immunohistochemistry,IHC)技术和TCGA分析SMARCB1在HCC组织和正常组织的表达情况,阐述其在HCC发生、发展进程中的作用。结果:IHC结果证实,与正常肝组织相比,HCC中SMARCB1的蛋白表达量显著上升(P<0.01)。IHC的结果显示SMARCB1的蛋白表达量与原发肿瘤分期呈正相关(P<0.05),即SMARCB1表达量越高,原发肿瘤分期越趋向晚期。TCGA的结果显示SMARCB1的高表达是HCC的独立预后因素(P<0.05)。结论:SMARCB1可能起着促癌基因的作用,临床上根据其在组织中的表达差异,可鉴别早期的HCC及良性组织,并可能有效地进行预后判断。
Objective: To investigate the role of SMARCB1 in the early diagnosis and prognosis of hepatocellular carcinoma (HCC). Methods: The SMARCB1 gene was screened from the database of Cancer Genome Atlas (TCGA). The expression of SMARCB1 in HCC tissues and normal tissues was analyzed by immunohistochemistry (IHC) and TCGA. HCC occurred, the role of development process. Results: The results of IHC confirmed that the protein expression of SMARCB1 in HCC was significantly increased compared with normal liver tissues (P <0.01). The results of IHC showed that the protein expression of SMARCB1 was positively correlated with the primary tumor stage (P <0.05). The higher the level of SMARCB1 was, the more staged the primary tumor was. The results of TCGA showed that the high expression of SMARCB1 was an independent prognostic factor for HCC (P <0.05). Conclusion: SMARCB1 may play a role in promoting oncogenes. Clinically, according to its expression differences in tissues, it can identify early stage HCC and benign tissues, and may be useful for prognostic judgment.